Stock MSB MESOBLAST LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Mesoblast Limited

Equities

MSB

AU000000MSB8

Market Closed - Australian S.E.
Other stock markets
 02:10:03 2024-07-08 am EDT 		5-day change 1st Jan Change
1.12 AUD +1.36% Intraday chart for Mesoblast Limited +13.13% +261.29%
Jul. 02 Mesoblast to File Biological License Application with US FDA for Cellular Therapy MT
Jul. 01 Mesoblast to File Biologics License Application for Ryoncil MT

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Mesoblast to File Biological License Application with US FDA for Cellular Therapy
Mesoblast to File Biologics License Application for Ryoncil
Mesoblast to File Biologics License Application for Ryoncil FDA Approval Next Week
Mesoblast Limited Announces Board and Committee Changes
FDA Says Mesoblast Trial Data Sufficient to Support BLA Submission
Sector Update: Health Care Stocks Advance Late Afternoon
Top Midday Gainers
Sector Update: Health Care Stocks Steady Premarket Tuesday
Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading
Top Premarket Gainers
Mesoblast to Resubmit Application for Potential Pediatric Treatment of Graft Versus Host Disease; Shares Gain Pre-Bell
United States Food & Drug Administration Notifies Mesoblast Limited of Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease
Mesoblast Raises AU$97 Million From Entitlement Offer, Institutional Placement
Mesoblast Raises AU$97 Million for Phase Three Registration Trials
Sector Update: Health Care Stocks Softer Late Afternoon
Sector Update: Health Care Stocks Decline in Afternoon Trading
Sector Update: Health Care
Top Stories at Midday: Bally's Gets Takeover Proposal; Eli Lilly's Eczema Study Results; Reddit's Expected IPO Price Range; FDA Backs Mesoblast Heart Therapy's Approval Pathway
Sector Update: Health Care Stocks Lean Lower Premarket Monday
Mesoblast Secures Backing from US FDA for Potential Fast-Track Approval of Heart Failure Treatment
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MSB Stock
  4. News Mesoblast Limited
  5. Other languages